According to findings of a study published in the journal Research in Developmental Disabilities, data from a private U.S. cord blood bank registry may offer key information to patients with cerebral palsy. Cord blood contains stem cells, a type of cell that may promote the repair of damaged tissues, and has been used as a treatment for cerebral palsy.
The registry referenced in the study, Longitudinal Umbilical Stem cell Monitoring and Treatment Research (LUSTRE), was established to study clinical characteristics of children with neurological disorders. For this study, researchers compared statistics from children enrolled in LUSTRE that were diagnosed with cerebral palsy (such as demographics, mobility, and gross motor function) to children diagnosed with cerebral palsy enrolled in a different registry, Autism and Developmental Disabilities Monitoring (ADDM) Network. “The results of this analysis suggest that while children diagnosed with cerebral palsy and with access to stored cord blood differ from a broader population sample in terms of demographics, they have similar clinical severity and co-morbidity profiles,” the researchers said. “As such, LUSTRE may serve as a valuable source of data for the characterization of individuals with cerebral palsy, including individuals who have or will receive cord blood infusions.”
The following reviews from our clients do not constitute a guarantee, warranty, or prediction regarding the outcome of another legal matter. The cases mentioned in the reviews are illustrative of some of the matters previously handled by Grant & Eisenhofer involving various areas of birth injury law. These reviews are endorsements.